COMMUNIQUÉS West-GlobeNewswire

OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
27/02/2026
MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South [...]
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
27/02/2026
Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA [...]
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
27/02/2026
Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipeline Potentially unlocks multi-billion-dollar [...]
OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry
27/02/2026
MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today [...]
The Standard Process Brand Evolution Elevates Awareness of Whole Food Nutrition
27/02/2026
The company’s 97-year commitment to restore nutritional integrity as the foundation of health A Media Snippet accompanying this announcement is available by clicking on this link. PALMYRA, Wis., Feb. 27, 2026 (GLOBE [...]
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering
27/02/2026
OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead [...]
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
27/02/2026
• EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Feb. 27, 2026 (GLOBE [...]
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
27/02/2026
MELBOURNE, Australia and INDIANAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospital Essen on the [...]
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
27/02/2026
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease [...]
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
27/02/2026
- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare [...]
Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF
27/02/2026
S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec [...]
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
27/02/2026
‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million ; GAAP Net Income of $35 million ; Diluted Income per Share of $0.11 [...]
Tidewave Bio Appoints Prof. Alexander M.M. Eggermont, MD, PhD, as Head of Clinical Advisory Board
27/02/2026
LOS ANGELES, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Tidewave Bio, a biotechnology company developing a universal, biopsy-native immunotherapy platform for solid tumors, today announced the appointment of Prof. Alexander M.M [...]
BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
27/02/2026
LOUISVILLE, Ky., Feb. 27, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex [...]
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
27/02/2026
If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of [...]
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
27/02/2026
Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Recommendation based on phase 2/3 study demonstrating [...]
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
27/02/2026
Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first targeted medicine in [...]
OrthoPediatrics to Participate in Upcoming Conferences
27/02/2026
WARSAW, Ind., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Communiqué de presse : Dupixent de Sanofi et Regeneron recommandé pour approbation dans l'UE dans le traitement de l'urticaire chronique spontanée chez les jeunes enfants dont les symptômes persistent malgré un traitement
27/02/2026
Dupixent de Sanofi et Regeneron recommandé pour approbation dans l'UE dans le traitement de l'urticaire chronique spontanée chez les jeunes enfants dont les symptômes persistent malgré un traitement S’il est approuvé, [...]

Pages